Thursday, November 12, 2026

BMO Exit From AIR MILES Could Cut Loyalty Program Revenue 15-25% by 2027

Bank of Montreal's shift away from AIR MILES to a proprietary loyalty program threatens to reduce the Canadian program's transaction volume by up to a quarter over the next two years. The move directly impacts Diversified Royalty Corp, which owns AIR MILES through AM Royalties Limited Partnership and depends on transaction-based royalty streams.

BMO Exit From AIR MILES Could Cut Loyalty Program Revenue 15-25% by 2027
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Bank of Montreal announced January 26, 2026 its transition from AIR MILES to a new in-house loyalty program, a shift analysts project will cut AIR MILES' market share in Canadian loyalty programs by 15-25% through 2027.

Diversified Royalty Corp owns AIR MILES Reward Program through AM Royalties Limited Partnership. BMO serves dual roles as both an AIR MILES customer and guarantor of the partnership, making this departure financially material. The bank's exit removes a major transaction generator from a royalty-based revenue model.

The timing coincides with multiple partnership amendments and contract awards filed January 26, suggesting accelerated contract restructuring. These filings indicate AIR MILES is renegotiating relationships as it faces losing one of Canada's five largest banks.

Loyalty program economics depend on transaction volume. When major partners exit, remaining partners must compensate for lost activity or the program faces margin compression. AIR MILES collects royalties on transactions flowing through its network—fewer BMO credit card swipes and banking interactions mean lower royalty payments to Diversified Royalty Corp.

Canadian loyalty program consolidation has accelerated since 2020. Banks increasingly prefer proprietary programs that capture 100% of customer data and avoid sharing economics with third-party platforms. BMO's move follows a pattern where financial institutions calculate that direct customer relationships justify the cost of building loyalty infrastructure.

Diversified Royalty Corp investors should monitor Q1-Q4 2026 earnings for AIR MILES segment performance. Key metrics include program enrollment trends, redemption volumes, and revenue per active member. The company must disclose material changes to partnership agreements that affect royalty calculations.

The loyalty program market shows clear bifurcation: large financial institutions building proprietary systems versus retailers and smaller banks relying on established platforms like AIR MILES. BMO's departure tests whether multi-sponsor programs can maintain economics when anchor partners leave.

Air Miles Loyalty Inc operates the program infrastructure while AM Royalties Limited Partnership holds the intellectual property generating royalty streams. This structure means Diversified Royalty Corp faces revenue pressure without operational control over member retention strategies.

Quarterly tracking of BMO customer migration rates to the new program will determine whether the 15-25% revenue impact estimate holds. Fast migration accelerates AIR MILES revenue decline; slow migration provides time to replace lost volume with new partnerships.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com